Mode
Text Size
Log in / Sign up

Endovascular coil embolization provides durable aneurysm occlusion for Neurofibromatosis type 1 patientsCoil Embolization Works for Aneurysm in NF1 Patient

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that endovascular coil embolization provides durable occlusion but requires lifelong monitoring due to progressive symptoms.

This case report and literature review explores the management of a ruptured distal ACA aneurysm in a 44-year-old man with Neurofibromatosis type 1 (NF1). The authors synthesize clinical observations regarding the use of endovascular coil embolization as an intervention for aneurysms in this specific patient population.

The primary finding is that endovascular coil embolization resulted in complete aneurysm occlusion while preserving the parent artery. Follow-up lasting more than five years confirmed durable occlusion. However, the report notes that Moyamoya syndrome progressed and a new, untreated aneurysm was identified at the right ophthalmic segment during the follow-up period.

A significant limitation of this evidence is the small sample size of one patient. The authors note that while endovascular coil embolization is considered a safe and effective first-line treatment for ruptured distal ACA aneurysms in NF1 patients, the underlying condition remains progressive. Clinical management requires lifelong monitoring due to the risk of new aneurysm formation and progression of associated conditions like Moyamoya syndrome.

How this fits prior evidence

This case report addresses a gap in managing specific vascular complications in Neurofibromatosis type 1. It builds upon previous reports where NF1 patients presented with hematomas or other masses, reinforcing the need for prompt imaging and intervention in these cases. While this report confirms that endovascular coil embolization is an effective treatment for aneurysm occlusion, it highlights the progressive nature of the disease, which was also noted in other reported cases involving complex tumors and complications in NF1 patients.

A case report describes a 44-year-old man with neurofibromatosis type 1 (NF1) who had a ruptured brain aneurysm. Doctors used a minimally invasive procedure called endovascular coil embolization to block the aneurysm. The treatment was successful: the aneurysm was completely occluded, and the artery was preserved. The patient recovered neurologically.

However, the man's underlying condition, moyamoya syndrome, continued to progress. Over more than five years of follow-up, a new aneurysm developed on the right ophthalmic segment. This shows that while the initial treatment worked, NF1 and moyamoya syndrome are progressive and require ongoing monitoring.

This is a single case report, so the results cannot be generalized to all NF1 patients. The study did not compare coil embolization to other treatments like surgical clipping. No side effects or complications from the procedure were reported.

For people with NF1 and aneurysms, coil embolization may be a safe and effective option, but lifelong surveillance is needed. Talk to your doctor about the best treatment plan for your specific situation.

What this means for you:
Coil embolization can treat aneurysms in NF1, but the disease requires lifelong monitoring.

Common questions

What is endovascular coil embolization?

It is a minimally invasive procedure where a catheter is threaded through blood vessels to place coils inside an aneurysm, blocking blood flow and preventing rupture.

Is coil embolization safe for NF1 patients?

In this single case report, the procedure was safe and effective, with complete aneurysm occlusion and no reported complications. However, more research is needed.

Does the treatment cure NF1 or moyamoya syndrome?

No. The treatment addressed the aneurysm, but the underlying moyamoya syndrome progressed, and a new aneurysm formed. Lifelong monitoring is essential.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundNeurofibromatosis type 1 (NF1) is a genetic disorder occasionally complicated by vasculopathy, but the concurrence of NF1, a ruptured distal anterior cerebral artery (ACA) aneurysm, and moyamoya syndrome is exceedingly rare. Literature review revealed that fewer than 20 such cases have been reported in English publications to date. The management of such complex, multifocal cerebrovascular pathology—including the choice of therapy, the risk of procedural complications, and the need for lifelong surveillance—poses significant challenges.Case descriptionA 44-year-old man with clinical features of NF1 presented with sudden headache, dizziness, and transient syncope. Imaging revealed a ruptured saccular aneurysm arising from the right A3 segment of the ACA, accompanied by intraventricular hemorrhage and contralateral moyamoya-like vasculopathy. Given the aneurysm's deep pericalosal location, small size, and the patient's multiple scalp neurofibromas, endovascular coil embolization was selected over microsurgical clipping. The procedure was successfully performed via a transfemoral approach, achieving complete aneurysm occlusion with preservation of the parent artery. The patient recovered well neurologically. Remarkably, digital subtraction angiography at more than five years post-embolization confirmed durable occlusion of the treated aneurysm without recurrence. However, it also demonstrated progression of the moyamoya syndrome and revealed a new, untreated aneurysm at the right ophthalmic segment.ConclusionThis case illustrates that endovascular coil embolization can be a safe and effective first-line treatment for ruptured distal ACA aneurysms in the complex setting of NF1 vasculopathy, providing long-term protection from rebleeding. The long-term follow-up uniquely highlights that NF1-associated cerebrovascular disease is progressive and multifocal; successful treatment of an index ruptured aneurysm does not eliminate the risk of new lesions elsewhere. Therefore, indefinite vascular surveillance is warranted in these patients. This report underscores the importance of a tailored, multidisciplinary approach and lifelong monitoring in managing NF1-related cerebrovascular complications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.